Skip to main content

Yesterday, Nov. 16, 2015, 86 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $1,470.50 to $10,820,124.97.

Highlighted Stocks Traded by Insiders:

Harris & Harris Group (TINY) - FREE Research Report

Jamison Douglas W, who is Chairman, CEO at Harris & Harris Group, bought 2,500 shares at $2.13 on Nov. 16, 2015. Following this transaction, the Chairman, CEO owned 202,779 shares meaning that the stake was boosted by 1.25% with the 2,500-share transaction.

The shares most recently traded at $2.16, up $0.03, or 1.25% since the insider transaction. Historical insider transactions for Harris & Harris Group go as follows:

  • 4-Week # shares bought: 15,998
  • 12-Week # shares bought: 17,643
  • 24-Week # shares bought: 38,500

The average volume for Harris & Harris Group has been 54,300 shares per day over the past 30 days. Harris & Harris Group has a market cap of $64.9 million and is part of the financial sector and financial services industry. Shares are down 28.81% year-to-date as of the close of trading on Monday.

Harris & Harris Group, Inc. is a venture capital firm specializing in early stage investments. It is a BDC. Currently, there are no analysts who rate Harris & Harris Group a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on TINY - FREE

TheStreet Quant Ratings

rates Harris & Harris Group as a

sell

. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full

Harris & Harris Group Ratings Report

Scroll to Continue

TheStreet Recommends

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Callidus Software (CALD) - FREE Research Report

Duan Jimmy C., who is EVP, Chief Technology Officer at Callidus Software, sold 11,081 shares at $20.16 on Nov. 16, 2015. Following this transaction, the EVP, Chief Technology Officer owned 268,215 shares meaning that the stake was reduced by 3.97% with the 11,081-share transaction.

The shares most recently traded at $19.67, down $0.49, or 2.49% since the insider transaction. Historical insider transactions for Callidus Software go as follows:

  • 4-Week # shares sold: 25,000
  • 12-Week # shares sold: 25,000
  • 24-Week # shares bought: 10,000
  • 24-Week # shares sold: 68,749

The average volume for Callidus Software has been 485,100 shares per day over the past 30 days. Callidus Software has a market cap of $1.1 billion and is part of the technology sector and computer software & services industry. Shares are up 19.9% year-to-date as of the close of trading on Monday.

Callidus Software Inc. provides enterprise software and related services to telecommunications, insurance, banking, and technology markets worldwide. Currently, there are 7 analysts who rate Callidus Software a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CALD - FREE

TheStreet Quant Ratings

rates Callidus Software as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we find that the company's return on equity has been disappointing. Get the full

Callidus Software Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Harvard Bioscience (HBIO) - FREE Research Report

Gagnon Robert E., who is Chief Financial Officer at Harvard Bioscience, bought 1,500 shares at $2.93 on Nov. 16, 2015. Following this transaction, the Chief Financial Officer owned 67,721 shares meaning that the stake was boosted by 2.27% with the 1,500-share transaction.

Historical insider transactions for Harvard Bioscience go as follows:

  • 4-Week # shares bought: 3,000
  • 4-Week # shares sold: 118,500
  • 12-Week # shares bought: 7,000
  • 12-Week # shares sold: 17,103
  • 24-Week # shares bought: 7,000
  • 24-Week # shares sold: 17,103

The average volume for Harvard Bioscience has been 122,000 shares per day over the past 30 days. Harvard Bioscience has a market cap of $101.5 million and is part of the health care sector and health services industry. Shares are down 47.09% year-to-date as of the close of trading on Monday.

Harvard Bioscience, Inc. develops, manufactures, and markets scientific instruments, systems, and lab consumables used in life science research. Currently, there is 1 analyst who rates Harvard Bioscience a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on HBIO - FREE

TheStreet Quant Ratings

rates Harvard Bioscience as a

sell

. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full

Harvard Bioscience Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.